Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1204692 | 0.88 | C5AR1 (0.39) | C5AR1ALDH1A1 | |
| SCHEMBL14521344 | 0.88 | RAB9A (0.34) | RAB9AKDM4EALDH1A1MAPTTSHR | |
| SCHEMBL1205772 | 0.87 | C5AR1 (0.39) | C5AR1SMN1; SMN2 | |
| SCHEMBL1206353 | 0.87 | RAB9A (0.33) | RAB9AKDM4EALDH1A1MAPTTSHR | |
| SCHEMBL1205735 | 0.86 | C5AR1 (0.40) | C5AR1 | |
| SCHEMBL12879076 | 0.85 | C5AR1 (0.38) | C5AR1RAB9AKDM4EALDH1A1MAPT | |
| SCHEMBL18329486 | 0.84 | C5AR1 (0.37) | C5AR1 | |
| SCHEMBL1205737 | 0.84 | ALDH1A1 (0.46) | KDM4EALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL12879077 | 0.83 | C5AR1 (0.37) | C5AR1RAB9AKDM4EALDH1A1MAPT | |
| SCHEMBL12879080 | 0.83 | C5AR1 (0.37) | C5AR1RAB9AKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884117-B2 | Protein kinase inhibitors such as (S)-2-(methylamino)-1-phenylethyl 3-(4-fluorobenzamido)-6,6-dimethylpyrrolo[3,4-c]pyrazole-5(1H,4H,6H)-carboxylate, used for the treatment of abnormal cell growth in mammals; antiproliferative agents | PFIZER INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884117-B2 | Protein kinase inhibitors such as (S)-2-(methylamino)-1-phenylethyl 3-(4-fluorobenzamido)-6,6-dimethylpyrrolo[3,4-c]pyrazole-5(1H,4H,6H)-carboxylate, used for the treatment of abnormal cell growth in mammals; antiproliferative agents | PFIZER INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20090318440-A1 | CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318440-A1 | CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER INC. | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318440-A1 | CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PAK4, PAK5, PAK3 | C5AR1 3945/4885RAB9A 1222/4885KDM4E 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.